盐酸坦索罗辛联合前列安栓治疗慢性盆底疼痛综合征的临床观察

将150例慢性盆底疼痛综合征患者按就诊先后顺序采用随机数字表及随机数余数分组法分成3组（各50例）,分别予盐酸坦索罗辛（THSRC）、前列安栓和THSRC±前列安栓联合治疗12周。治疗后慢性前列腺炎症状积分指数（NIH—CPSI）总分,THSRC组由治疗前的25．1±2．2下降到19．5±1．7（t=2．63,P〈0．01）,前列安栓组由治疗前的25．0±2．2下降到治疗后的19．1±1．7（t=2．47,P〈0．01）,THSRC±前列安栓组由治疗前的24．8±1．7下降到治疗后的16．8±1．4（t=3．22,P〈0．01）。提示,THSRC、前列安栓均能有效缓解慢性盆底疼痛综合征患者的症状,改善患者的生存质量,THSRC±前列安栓联合治疗疗效优于单一药物治疗。

Tamsulosin hydrochlorid combined with Qianlie'an Shuan in treatment of chronic pelvic pain syndrome

Total 150 patients with chronic pelvic pain syndrome were randomly divided into three groups with 50 cases in each group. Patients were treated with tamsulosin, Qianlie'an Shuan and tamsulosin plus Qianlie'an Shuan for 12 weeks, respectively. Patients were assessed with the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) before and after treatment. The score of NIH-CPSI decreased from 25. 1 ± 2. 2 to 19. 5 ± 1.7 after treatment in tamsulosin group; 25.0 ± 2. 2 to 19. 1 ± 1.7 in Qianlie'an Shuan group, and 24. 8 ± 1.7 to 16. 8 ± 1.4 in combined therapy group, all P ＜0. 01. The results indicated that tamsulosin, Qianlie' an Shuan or combined therapy were all effective in alleviating the symptoms and improving the quality of life, and the combined therapy was superior to single therapy in relief of symptoms.